182 related articles for article (PubMed ID: 38163441)
1. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment.
Sogbe M; Bilbao I; Marchese FP; Zazpe J; De Vito A; Pozuelo M; D'Avola D; Iñarrairaegui M; Berasain C; Arechederra M; Argemi J; Sangro B
Clin Mol Hepatol; 2024 Apr; 30(2):177-190. PubMed ID: 38163441
[TBL] [Abstract][Full Text] [Related]
2. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
[TBL] [Abstract][Full Text] [Related]
5. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
6. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
7. Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma.
Sato T; Montazeri K; Gragoudas ES; Lane AM; Aronow MB; Cohen JV; Boland GM; Banks E; Kachulis C; Fleharty M; Cibulskis C; Lawless A; Adalsteinsson VA; Sullivan RJ; Kim IK
JCO Precis Oncol; 2024 Jan; 8():e2300368. PubMed ID: 38237100
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
[TBL] [Abstract][Full Text] [Related]
9. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
Wang Y; Zhou K; Wang X; Liu Y; Guo D; Bian Z; Su L; Liu K; Gu X; Guo X; Wang L; Zhang H; Tao K; Xing J
Cancer Sci; 2021 Nov; 112(11):4772-4784. PubMed ID: 34490703
[TBL] [Abstract][Full Text] [Related]
10. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma.
Tao K; Bian Z; Zhang Q; Guo X; Yin C; Wang Y; Zhou K; Wan S; Shi M; Bao D; Yang C; Xing J
EBioMedicine; 2020 Jun; 56():102811. PubMed ID: 32512514
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA and Hepatocellular Carcinoma.
Yang JD; Liu MC; Kisiel JB
Semin Liver Dis; 2019 Nov; 39(4):452-462. PubMed ID: 31226727
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
15. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
16. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
[TBL] [Abstract][Full Text] [Related]
17. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
18. Detection and monitoring of HBV-related hepatocellular carcinoma from plasma cfDNA fragmentation profiles.
Sun X; Feng W; Cui P; Ruan R; Ma W; Han Z; Sun J; Pan Y; Zhu J; Zhong X; Li J; Ma M; Hu R; Lv M; Huang Q; Zhang W; Feng M; Zhuang X; Huang B; Zhou X
Genomics; 2022 Nov; 114(6):110502. PubMed ID: 36220554
[TBL] [Abstract][Full Text] [Related]
19. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.
Kim MH; Kim GM; Ahn JM; Ryu WJ; Kim SG; Kim JH; Kim TY; Han HJ; Kim JY; Park HS; Park S; Park BW; Kim SI; Jeong J; Lee J; Paik S; Kim S; Jung KH; Cho EH; Sohn J
J Natl Cancer Inst; 2023 Sep; 115(9):1036-1049. PubMed ID: 37166557
[TBL] [Abstract][Full Text] [Related]
20. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
